Question

Difficulty: Very hardHematology and Oncology

A 3838-year-old man is evaluated in the emergency department for progressive fatigue, severe epistaxis, and bleeding from his gums over the past two days. He has no significant past medical history and takes no medications. Vital signs are: Temperature 37.6∘C37.6^\circ\text{C} (99.7∘F99.7^\circ\text{F}), Blood pressure 100/60 mm Hg100/60 \text{ mm Hg}, Heart rate 112/min112/\text{min}, Respiratory rate 18/min18/\text{min}. Physical examination reveals marked mucosal pallor, continuous gingival oozing, and extensive coalescing petechiae and purpura over the trunk and bilateral lower extremities. Laboratory studies show:

Leukocyte count: 2,800/mm32,800/\text{mm}^3
- Neutrophils: 15%15\%
- Lymphocytes: 25%25\%
- Atypical cells: 60%60\%
Hemoglobin: 7.4 g/dL7.4 \text{ g/dL}
Platelet count: 15,000/mm315,000/\text{mm}^3
Prothrombin time: 24 seconds24 \text{ seconds}
Partial thromboplastin time: 54 seconds54 \text{ seconds}
Fibrinogen: 65 mg/dL65 \text{ mg/dL} (Normal: 150−400 mg/dL150-400 \text{ mg/dL})
D-dimer: 8,500 ng/mL8,500 \text{ ng/mL} (Normal: <500 ng/mL< 500 \text{ ng/mL})

Peripheral blood smear demonstrates predominant cells with bilobed nuclei and dense, coarse azurophilic granules. Several of these cells contain bundles of red-staining, needle-like cytoplasmic inclusions. Which of the following is the most appropriate initial step in the management of this patient?

  1. Administer all-trans retinoic acidAnswer
  2. B
    Perform bone marrow aspiration and karyotyping
  3. C
    Initiate induction chemotherapy with cytarabine and an anthracycline
  4. D
    Administer intravenous recombinant factor VIIa
  5. E
    Perform urgent leukapheresis

Answer

The most appropriate initial step is to administer all-trans retinoic acid (ATRA) immediately.
The patient's presentation of pancytopenia, severe coagulopathy (prolonged PT/aPTT, low fibrinogen, elevated D-dimer), and peripheral smear showing heavily granulated cells with bundles of Auer rods is highly characteristic of Acute Promyelocytic Leukemia (APL), the M3 subtype of acute myeloid leukemia. APL is driven by the t(15;17) translocation, which fuses the PML gene with the retinoic acid receptor alpha (RARA) gene, halting cellular differentiation at the promyelocyte stage. These abnormal promyelocytes contain primary granules rich in tissue factor and other procoagulants. When released, they trigger widespread Disseminated Intravascular Coagulation (DIC), making bleeding the leading cause of early mortality. The administration of all-trans retinoic acid (ATRA) overcomes this block, forcing the promyelocytes to differentiate and mature. This rapidly reverses the coagulopathy. Because of the high risk of catastrophic hemorrhage, ATRA must be started immediately based on clinical and morphological suspicion. Treatment should never be delayed pending cytogenetic or molecular confirmation.

Step-by-Step Solution

1
Analyze the clinical presentation and laboratory findings.
The patient has pancytopenia, severe bleeding, and laboratory evidence of Disseminated Intravascular Coagulation (DIC) as shown by prolonged PT/aPTT, low fibrinogen, and elevated D-dimer.
Identifying the life-threatening complication (DIC) is crucial for acute management.
2
Evaluate the peripheral blood smear description.
Atypical cells with bilobed nuclei, dense azurophilic granules, and bundles of Auer rods (faggot cells) are diagnostic for Acute Promyelocytic Leukemia (APL).
Morphology provides the immediate presumed diagnosis needed to initiate emergency targeted therapy.
3
Determine the next best step in management based on the presumed diagnosis of APL with DIC.
All-trans retinoic acid (ATRA) must be initiated immediately upon morphological suspicion.
ATRA drives the differentiation of malignant promyelocytes into mature neutrophils, halting the release of procoagulants and rapidly resolving the DIC. Waiting for cytogenetic confirmation before treatment is contraindicated.

Key Concept

Acute Promyelocytic Leukemia (APL) is a medical emergency that frequently presents with severe Disseminated Intravascular Coagulation (DIC). All-trans retinoic acid (ATRA) must be initiated immediately upon morphological suspicion to prevent fatal hemorrhage; treatment should never be delayed for cytogenetic confirmation.
Estimated Time:1m 30s
Rate this question